NCT00357500 - Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

February 28, 2013

Study Completion Date

December 31, 2013

Conditions

Central Nervous System Tumor, PediatricLeukemiaLymphomaNeuroblastomaSarcomaUnspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG

celecoxib

DRUG

cyclophosphamide

DRUG

etoposide

DRUG

fenofibrate

DRUG

thalidomide

Trial Locations (10)

10016

NYU Cancer Institute at New York University Medical Center, New York

55404

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis

60614

Children's Memorial Hospital - Chicago, Chicago

63110

St. Louis Children's Hospital, St Louis

06106

Connecticut Children's Medical Center, Hartford

33155-4069

Miami Children's Hospital, Miami

04074-7205

Maine Medical Center Research Institute, Scarborough

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

08903

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick

02903

Hasbro Children's Hospital, Providence

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Boston Children's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER